Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 29584548

Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2018 Aug 1
First author
Cheson BD

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2018 Aug 1;36(22):2323-2325. doi: 10.1200/JCO.2018.78.7390.
    note
    Source null
    related pmid
    29894272
    relationship
    Comment in

Authors and identifiers

  1. name
    Cheson BD
    type
    Author
  2. name
    Chua N
    type
    Author
  3. name
    Mayer J
    type
    Author
  4. name
    Dueck G
    type
    Author
  5. name
    Trněný M
    type
    Author
  6. name
    Bouabdallah K
    type
    Author
  7. name
    Fowler N
    type
    Author
  8. name
    Delwail V
    type
    Author
  9. name
    Press O
    type
    Author
  10. name
    Salles G
    type
    Author
  11. name
    Gribben JG
    type
    Author
  12. name
    Lennard A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cheson BD
    type
    Author
  2. name
    Chua N
    type
    Author
  3. name
    Mayer J
    type
    Author
  4. name
    Dueck G
    type
    Author
  5. name
    Trněný M
    type
    Author
  6. name
    Bouabdallah K
    type
    Author
  7. name
    Fowler N
    type
    Author
  8. name
    Delwail V
    type
    Author
  9. name
    Press O
    type
    Author
  10. name
    Salles G
    type
    Author
  11. name
    Gribben JG
    type
    Author
  12. name
    Lennard A
    type
    Author
bibliography ids
  1. nci-bib-b7e22520747ace2250502853
book metadata
content sha256
16a2fe034af6e584462dc375483278f4db6f52b64d74aaeef81b64287d3eb0c7
document type
citation
dois
  1. 10.1200/JCO.2017.76.3656
electronic publication date
display
2018 Mar 27
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29584548
immutable id
pubmed:29584548@16a2fe034af6e584462dc375483278f4db6f52b64d74aaeef81b64287d3eb0c7
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
22
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2259-2266
volume
36
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2018 Aug 1;36(22):2323-2325. doi: 10.1200/JCO.2018.78.7390.
    note
    Source null
    related pmid
    29894272
    relationship
    Comment in
outcomes validated
false
pmid
29584548
provenance
batch id
ec9444d0f4cade22eb9f
provider
NCBI PubMed ESummary
record sha256
e428e933ac2bdca030b1a661538fb7767ef33560735603fec94fa6fca37d1285
response sha256
6eef0d8cc09b77e73af656f6390cc734befb84fbc4c229b886e81e5d95bece31
retrieved at
2026-09-09T23:47:30.975610+00:00
publication date
display
2018 Aug 1
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29584548/
title
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Preserved source evidence · Independent clinical review pending · Not medical advice